Sarah E. Hoffe
A5035589941- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Esophageal and GI Pathology
- Cancer Genomics and Diagnostics
- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Surgical Treatments
- Medical Imaging Techniques and Applications
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Advances in Oncology and Radiotherapy
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Treatments and Studies
- Glioma Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Pancreatitis Pathology and Treatment
- Radiation Therapy and Dosimetry
- MRI in cancer diagnosis
Moffitt Cancer Center
2016-2025
Radiation Oncology Associates
2015-2021
Yale University
2021
University of Wisconsin Carbone Cancer Center
2021
University of South Florida
2009-2018
Sarasota Memorial Hospital
2015-2016
University of Central Florida
2016
Florida State University
2016
Digestive Care (United States)
2016
Society of Interventional Radiology
2016
This portion of the NCCN Guidelines for Colon Cancer focuses on use systemic therapy in metastatic disease. Considerations treatment selection among 32 different monotherapies and combination regimens up to 7 lines have included history, extent disease, goals treatment, efficacy toxicity profiles regimens, KRAS/NRAS mutational status, patient comorbidities preferences. Location primary tumor, BRAF mutation tumor microsatellite stability should also be considered decisions.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These include recommendations first-line use checkpoint inhibitors mCRC, that is deficient mismatch repair/microsatellite instability-high, related biosimilars, and expanded biomarker testing. The now targeted patients with mCRC...
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, survivorship. These Insights summarize the Panel discussions 2018 update guidelines risk stratification adjuvant treatment patients with stage III colon cancer,
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, survivorship patients with rectal cancer. This portion the guidelines focuses on localized which involves careful patient selection curative-intent treatment options that sequence multimodality therapy usually comprised chemotherapy, radiation, resection.
This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent include redrawing algorithms stage II III disease reflect new data supporting increasingly prominent role total neoadjuvant therapy, expanded recommendations short-course radiation therapy techniques, a "watch-and-wait" nonoperative technique patients with that shows complete...
The NCCN Guidelines for Rectal Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These Insights summarize panel discussion behind recent important updates to guidelines. include clarifying definition rectum differentiating from sigmoid colon; total neoadjuvant therapy approach localized cancer; biomarker-targeted metastatic colorectal cancer, a focus on new treatment options BRAF V600E- or HER2 amplification-positive disease.
Purpose. Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer.Material methods. We updated our institutional outcomes with a chemotherapy stereotactic body radiotherapy (SBRT) approach. An IRB-approved analysis was performed all BRPC LAPC patients treated departmental protocol. After staging, medically fit underwent for 2–3 months, regimen at the discretion treating medical oncologist. Patients then received...
Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than other related malignancies, including colorectal cancer. Due to rarity this disease, few studies have been done direct optimal treatment, although data shown responds treatment differently cancer, necessitating separate approach treatment. The NCCN Guidelines Bowel...
Colorectal cancer (CRC) is the fourth most frequently diagnosed and second leading cause of death in United States. Management disseminated metastatic CRC involves various active drugs, either combination or as single agents. The choice therapy based on consideration goals therapy, type timing prior mutational profile tumor, differing toxicity profiles constituent drugs. This manuscript summarizes data supporting systemic options recommended for NCCN Guidelines Colon Cancer.
This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents most common histologic form of disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical radiation and radiology is necessary. Primary treatment perianal cancer canal are similar include chemoradiation in cases. Follow-up clinical evaluations recommended all patients with carcinoma because additional curative-intent...
The determination of an optimal treatment plan for individual patient with rectal cancer is a complex process. In addition to decisions relating the intent surgery (ie, curative or palliative), consideration must also be given likely functional results treatment, including probability maintaining restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly patients distal cancer, finding balance between curative-intent therapy while having minimal...
TNFerade biologic is a novel means of delivering tumor necrosis factor alpha to cells by gene transfer. We herein report final results the largest randomized phase III trial performed date among patients with locally advanced pancreatic cancer (LAPC) and first test transfer against this malignancy.In all, 304 were randomly assigned 2:1 standard care plus (SOC + TNFerade) versus alone (SOC). SOC consisted 50.4 Gy in 28 fractions concurrent fluorouracil (200 mg/m(2) per day continuous...
The NCCN Guidelines for Anal Carcinoma provide recommendations the management of patients with squamous cell carcinoma anal canal or perianal region. Primary treatment cancer usually includes chemoradiation, although certain lesions can be treated margin-negative local excision alone. Disease surveillance is recommended all because additional curative-intent possible. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical radiation and radiology...
Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cancer precursors incidentally discovered by cross-sectional imaging. Consensus guidelines for IPMN management rely on standard radiologic features to predict pathology, but they lack accuracy. Using a retrospective cohort of 38 surgically-resected, pathologically-confirmed IPMNs (20 benign; 18 malignant) with preoperative computed tomography (CT) images and matched plasma-based 'miRNA genomic classifier (MGC)' data, we...
Abstract Background and Objectives To improve the likelihood of achieving a margin‐free resection, neoadjuvant induction chemotherapy with GTX (gemcitabine, docetaxel, capecitabine) followed by 5‐FU‐IMRT was administered to patients borderline resectable pancreatic cancer. The utility computed tomography (CT), endoscopic ultrasound (EUS), positron emission (PET), CA 19‐9 during diagnostic workup assessment response also examined. Methods Seventeen cancer received median three cycles dose...